Youn B, et al. - By utilizing the Surveillance, Epidemiology, and End Results–Medicare linked database, researchers assessed patient features and overall survival from the time of immune checkpoint inhibitor start through December 31, 2017, among older adults (n = 1,256, aged ≥ 65 years) with pathologically confirmed stage I to stage IV non–small cell lung cancer (NSCLC) who initiated nivolumab or pembrolizumab in 2016. Following starting immune checkpoint inhibitor, the median overall survival was estimated to be 9.3 months. The 1-year survival rate was estimated to be 43.0%. A statistically significant link with an increased hazard of death was shown by factors such as multiple comorbid conditions, squamous histology, a history of nonplatinum doublet systemic therapy, recent radiotherapy, and a shorter time from the initial diagnosis to therapy start, in multivariable analyses. Findings revealed the presence of multiple comorbidities, a history of autoimmune disease, or poor performance status among many older adults with NSCLC who started immune checkpoint inhibitors. The factors related to poor prognosis in advanced NSCLC cases were also found to be linked to worse survival among older adults managed with immune checkpoint inhibitors.